Beam Therapeutics Q3 EPS $(1.22) Beats $(1.34) Estimate, Sales $17.19M Miss $17.49M Estimate
Portfolio Pulse from Benzinga Newsdesk
Beam Therapeutics reported Q3 losses of $(1.22) per share, beating the analyst consensus estimate of $(1.34) by 8.96%. However, the company's quarterly sales of $17.19 million missed the analyst consensus estimate of $17.49 million by 1.70%. This represents a 21.79% increase in losses and an 8.82% increase in sales compared to the same period last year.
November 08, 2023 | 11:31 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Beam Therapeutics' Q3 earnings per share beat estimates, but sales missed expectations. This mixed report may lead to uncertainty in the market.
Beam Therapeutics reported better than expected earnings per share, which is a positive signal for investors. However, the company's sales missed estimates, which could be a concern. This mixed report may lead to uncertainty in the market, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100